Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
about
Management of gastric and duodenal neuroendocrine tumorsThe stomach in health and diseaseAutoimmune atrophic gastritis: current perspectives.A knockin mouse model for human ATP4aR703C mutation identified in familial gastric neuroendocrine tumors recapitulates the premalignant condition of the human disease and suggests new therapeutic strategies.Review article: the investigation and management of gastric neuroendocrine tumours.Novel roles of gastrin.Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.Follow-up of patients with ECL cell-derived tumours.Pathophysiology of Gastric NETs: Role of Gastrin and Menin.Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.A case of mixed adenoneuroendocrine carcinoma of the stomach with focal intestinal metaplasia and hypergastrinemia.Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.Cell cycle dependent expression of the CCK2 receptor by gastrointestinal myofibroblasts: putative role in determining cell migration.Somatostatin analogs for gastric carcinoids: For many, but not all.Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use.Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells.Medical Therapy of Gastrointestinal Neuroendocrine Tumors.Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
P2860
Q26738541-A7E16926-18B4-4661-B5A2-8CE31FC9EE75Q26784036-C4280B87-E3AB-494C-9CC0-6014FFB7D05CQ30235618-121D4E0D-021F-4D20-95D6-ACD060A14AD4Q37305896-C45AB5B4-10D7-4FB0-BC80-98B20B8B0FF2Q38195905-2F376157-4B5F-4E38-9023-6579AAF767B9Q38199081-2210C90A-E0E3-4BBF-97B1-195657B26800Q38205916-AA0AD582-94B5-4F3A-BF15-8A831F172DC4Q38866858-FA0AE4C3-B3DB-430F-BAB2-53CA712FCCADQ39368598-167DE7F1-D75F-4DF1-AD5B-39A739A65247Q39669592-B46B5333-2430-4218-8F4B-2B2561900857Q41416234-0856413A-174B-4D96-9A00-39E0F7CA154FQ41458940-C5E8D41A-8F78-4C75-A598-E355FAD0FF5FQ42378089-AC988AE2-E100-4142-BF9E-112D753C9CD4Q42533692-EE612746-5946-4DE6-A981-3DA5B953D2FAQ46270157-2CDC85B1-D1A0-4E8F-860F-1194A9DD5AC4Q47694700-A6C305A2-3D58-4BE0-8118-D86C6307F4A2Q47816626-BE71738D-9427-441B-85C9-FE83CE473655Q51430102-03AA66C5-949B-4A9A-8665-0B1412FFAD6F
P2860
Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Netazepide, a gastrin receptor ...... th chronic atrophic gastritis.
@ast
Netazepide, a gastrin receptor ...... th chronic atrophic gastritis.
@en
type
label
Netazepide, a gastrin receptor ...... th chronic atrophic gastritis.
@ast
Netazepide, a gastrin receptor ...... th chronic atrophic gastritis.
@en
prefLabel
Netazepide, a gastrin receptor ...... th chronic atrophic gastritis.
@ast
Netazepide, a gastrin receptor ...... th chronic atrophic gastritis.
@en
P2093
P2860
P1433
P1476
Netazepide, a gastrin receptor ...... th chronic atrophic gastritis.
@en
P2093
Andrea Varro
Andrew R Moore
Fiona Campbell
Islay A Steele
P2860
P304
P356
10.1371/JOURNAL.PONE.0076462
P407
P577
2013-10-01T00:00:00Z